Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunoproteasome-Targeted Oncology and Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PSME1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PSME1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PSME1 Products |
| Gene Delivery | PSME1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PSME1 Products |
| Benchmark Ab | Anti-PSME1 Recombinant Antibody Recombinant positive control. |
View PSME1 Products |
| Validator | PSME1 siRNA Set For knockdown verification. |
View PSME1 Products |
| Related Target A | PSME2 Forms hetero-heptamer complex with PSME1 to activate the immunoproteasome. |
View PSME2 Products |
| Related Target B | PSMB8 Immunoproteasome catalytic subunit LMP7, synergistic in antigen presentation assays. |
View PSMB8 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Validation of PA28αβ hetero-oligomerization | High-purity, sequence-verified PSME1 and PSME2 proteins for precise in vitro reconstitution. |
| Off-target screening against constitutive proteasome subunits | Homolog panel proteins strictly verified by mass spec to guarantee assay specificity. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live PSME1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PSME1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to small molecule inhibitors and PROTACs that modulate proteasomal degradation pathways. As first-generation therapies reach the clinic, the next wave of R&D is targeting the selective inhibition of the immunoproteasome over the constitutive proteasome to treat autoimmune disorders and hematological malignancies without systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Academic/Pharma Consortia | Autoimmune Diseases, Inflammatory Disorders | Selectivity Assay (Need Mutant vs WT Proteins) |
| PROTAC | Biotech Startups | Multiple Myeloma, Solid Tumors | Target Degradation Validation (Need Lentivirus for Stable Cell Lines) |
| Peptide Therapeutics | Immunotherapy Developers | Oncology (Antigen Presentation Enhancement) | Protein-Protein Interaction (PPI) Assays (Need High-Purity ECD-Fc/Recombinant Proteins) |